Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  KOREA EXCHANGE (KOSDAQ)  >  Celltrion HealthCare Co Ltd    A091990   KR7091990002

CELLTRION HEALTHCARE CO LTD

(A091990)
  Report
 SummaryNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Financials
Sales 2020 1 747 B 1,58 B 1,58 B
Net income 2020 296 B 0,27 B 0,27 B
Net cash position 2020 453 B 0,41 B 0,41 B
P/E ratio 2020 72,7x
Yield 2020 0,01%
Sales 2021 2 241 B 2,03 B 2,03 B
Net income 2021 354 B 0,32 B 0,32 B
Net cash position 2021 713 B 0,65 B 0,65 B
P/E ratio 2021 61,8x
Yield 2021 0,01%
Capitalization 21 443 B 19 443 M 19 449 M
EV / Sales 2020 12 276x
EV / Sales 2021 9 568x
Nbr of Employees -
Free-Float 58,9%
More Financials
Company
Celltrion Healthcare Co Ltd is a Korea-based company principally engaged in the marketing and distribution of biopharmaceuticals. The Company provides Remsima, an infliximab biosimilar used for the treatment of rheumatoid arthritis, ankylosing spondylitis, adult and child crohn’s disease, psoriasis, psoriatic arthritis and ulcerative colitis. It also offers Truxima, a rituximab biosimilar used for the treatment of... 
Sector
Pharmaceuticals
Calendar
-
More about the company
Notations Surperformance© of Celltrion HealthCare Co Ltd
Trading Rating : Investor Rating :
More Ratings
All news about CELLTRION HEALTHCARE CO LTD
2020CELLTRION HEALTHCARE : Seeks South Korean Approval for Emergency Use of Covid-19..
DJ
2020CELLTRION HEALTHCARE : says Phase 1 trial shows COVID-19 antibody drug 'well-tol..
RE
2020South Korea pharma Celltrion's COVID test gets U.S. emergency use authorisati..
RE
2020S.Korea pharma Celltrion's COVID test gets U.S. emergency use authorisation
RE
2020S.Korea shares jump most in two weeks on falling virus cases, upbeat China da..
RE
2020Investors swamp IPO for K-Pop band BTS management label, prices at top of ran..
RE
2020South Korea's Celltrion to merge with affiliates to set up holding company st..
RE
2020SK Biopharmaceuticals prices at top of range for South Korea's biggest IPO in..
RE
More news
News in other languages on CELLTRION HEALTHCARE CO LTD

- No features available -

More news
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 131 030,45 KRW
Last Close Price 140 000,00 KRW
Spread / Highest target 35,7%
Spread / Average Target -6,41%
Spread / Lowest Target -64,3%
EPS Revisions
Managers and Directors
NameTitle
Hyung-Ki Kim Chief Executive Officer & Director
Jung-Jin Seo Chairman
David Han Independent Director
Eung-Yeol Choe Independent Director
Un-Gab Jeong Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CELLTRION HEALTHCARE CO LTD19 299
CSL LIMITED-4.25%93 519
SAMSUNG BIOLOGICS CO.,LTD.-3.63%47 194
BIOGEN INC.12.65%42 447
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.-10.55%34 810
ALEXION PHARMACEUTICALS, INC.0.29%34 293